Promise of in vivo drug production sets off an mRNA arms race

Biotech researchers have long strived to use the body's natural resources to treat disease, whether by galvanizing the immune system or spurring the production of helpful materials. And thanks to some recent breakthroughs, a bevy of companies are pushing forward with messenger RNA, or mRNA, projects designed to turn human cells into in vivo drug factories. As Reuters notes, private biotechs CureVac, Moderna Therapeutics and BioNTech are developing mRNA treatments that can key the production of therapeutic proteins inside the body, raising hundreds of millions of dollars in venture investments and partnering dollars along the way. More

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.